Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data
IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood) improved an average of 54%, disease manifestations as measured by a venous clinical severity scores ( VCSS ) improved 56%, and pain, as measured on a visual analog scale ( VAS ), improved 76%, all at one-year post VenoValve surgery when compared to pre-surgery levels. Safety for all patients was assessed as well at one year.
Share:
Gainers
Sio Gene Therapies (NASDAQ: SIOX) shares are trading higher after the company announced positive six-month follow-up data from a low-dose cohort of Phase 1/2 trial of AXO-AAV-GM1.
Good Times Restaurants (NASDAQ: GTIM) shares are trading higher after the company announced Q4 EPS results were higher year over year.
Hancock Jaffe Laboratories (NASDAQ: HJLI) shares are trading higher after the company announced significant improvements in all study endpoints for final VenoValve first-in-human data.
Tilray (NASDAQ: TLRY) shares are trading higher on reports the company is in advanced merger talks with Aphria.
Aphria (NASDAQ: APHA) shares are trading higher on reports the company is in advanced merger talks with Tilray.
Hancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve Patient albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve Patient
IRVINE, CA / ACCESSWIRE /
, 2020 /
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the eleventh and final VenoValve patient in HJLI s first-in-human, clinical study has successfully reached the one-year milestone. Patient 11 s chronic venous insufficiency ( CVI ) has dramatically improved when compared to pre-surgery levels, with reflux (the backwards flow of blood) improving 70%, disease manifestations, as measured by a venous clinical severity scores ( VCSS ) improving 69%, and pain, as measured on a visual analog scale ( VAS ), improving 100%.
Hancock Jaffe Laboratories : Announces One Year Follow-up Data on Eleventh VenoValve Patient marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.